Literature DB >> 28804126

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.

M A Hoechstetter1, R Busch2, B Eichhorst3, A Bühler4, D Winkler4, M J Eckart5, U Vehling-Kaiser6, H Schimke7, U Jäger8, H J Hurtz9, G Hopfinger10, F Hartmann11, H Fuss12, W Abenhardt13, I Blau14, W Freier15, L Müller16, M Goebeler17, C M Wendtner1,3, J Bahlo3, K Fischer3, M Bentz18, B Emmerich19, H Döhner4, M Hallek3, S Stilgenbauer4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28804126     DOI： 10.1038/leu.2017.246

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

Review 1.  On the architecture of translational research designed to control chronic lymphocytic leukemia.

Authors:  Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.

Authors:  Kirsten Fischer; Othman Al-Sawaf; Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

3.  Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).

Authors:  Sonia Jaramillo; Andreas Agathangelidis; Christof Schneider; Jasmin Bahlo; Sandra Robrecht; Eugen Tausch; Johannes Bloehdorn; Manuela Hoechstetter; Kirsten Fischer; Barbara Eichhorst; Valentin Goede; Michael Hallek; Hartmut Döhner; Richard Rosenquist; Paolo Ghia; Kostas Stamatopoulos; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2019-12-26       Impact factor: 9.941

4.  PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.

Authors:  Christopher Ronald Funk; Shuhua Wang; Kevin Z Chen; Alexandra Waller; Aditi Sharma; Claudia L Edgar; Vikas A Gupta; Shanmuganathan Chandrakasan; Jaquelyn T Zoine; Andrew Fedanov; Sunil S Raikar; Jean L Koff; Christopher R Flowers; Silvia Coma; Jonathan A Pachter; Sruthi Ravindranathan; H Trent Spencer; Mala Shanmugam; Edmund K Waller
Journal:  Blood       Date:  2022-01-27       Impact factor: 25.476

5.  Acalabrutinib in treatment-naive chronic lymphocytic leukemia.

Authors:  John C Byrd; Jennifer A Woyach; Richard R Furman; Peter Martin; Susan O'Brien; Jennifer R Brown; Deborah M Stephens; Jacqueline C Barrientos; Stephen Devereux; Peter Hillmen; John M Pagel; Ahmed Hamdy; Raquel Izumi; Priti Patel; Min Hui Wang; Nitin Jain; William G Wierda
Journal:  Blood       Date:  2021-06-17       Impact factor: 25.476

Review 6.  Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?

Authors:  Junji Suzumiya; Jun Takizawa
Journal:  Int J Hematol       Date:  2020-04-06       Impact factor: 2.319

7.  Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.

Authors:  Carmen D Herling; Florence Cymbalista; Carolin Groß-Ophoff-Müller; Jasmin Bahlo; Sandra Robrecht; Petra Langerbeins; Anna-Maria Fink; Othman Al-Sawaf; Raymonde Busch; Raphael Porcher; Bruno Cazin; Brigitte Dreyfus; Stefan Ibach; Stéphane Leprêtre; Kirsten Fischer; Florian Kaiser; Barbara Eichhorst; Clemens-Martin Wentner; Manuela A Hoechstetter; Hartmut Döhner; Veronique Leblond; Michael Kneba; Remi Letestu; Sebastian Böttcher; Stephan Stilgenbauer; Michael Hallek; Vincent Levy
Journal:  Leukemia       Date:  2020-02-18       Impact factor: 11.528

Review 8.  Precision Medicine Management of Chronic Lymphocytic Leukemia.

Authors:  Riccardo Moia; Andrea Patriarca; Mattia Schipani; Valentina Ferri; Chiara Favini; Sruthi Sagiraju; Wael Al Essa; Gianluca Gaidano
Journal:  Cancers (Basel)       Date:  2020-03-10       Impact factor: 6.639

9.  A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.

Authors:  Jared A Cohen; Francesca Maria Rossi; Antonella Zucchetto; Riccardo Bomben; Lodovico Terzi-di-Bergamo; Kari G Rabe; Massimo Degan; Agostino Steffan; Jerry Polesel; Enrico Santinelli; Idanna Innocenti; Giovanna Cutrona; Giovanni D'Arena; Gabriele Pozzato; Francesco Zaja; Annalisa Chiarenza; Davide Rossi; Francesco Di Raimondo; Luca Laurenti; Massimo Gentile; Fortunato Morabito; Antonino Neri; Manlio Ferrarini; Christopher D Fegan; Christopher J Pepper; Giovanni Del Poeta; Sameer A Parikh; Neil E Kay; Valter Gattei
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941

Review 10.  Current Treatment Options in CLL.

Authors:  Moritz Bewarder; Stephan Stilgenbauer; Lorenz Thurner; Dominic Kaddu-Mulindwa
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.